{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:55:58Z","timestamp":1787025358876,"version":"build-2736575974"},"reference-count":26,"publisher":"Oceanside Publications Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Hereditary angioedema (HAE) is a rare genetic disorder characterized by painful, debilitating, and potentially fatal swelling attacks. Lanadelumab is approved as long-term prophylaxis (LTP) in patients with HAE. However, real-world data on LTP use in patients\n with HAE are limited.\n                    <jats:bold>Objective:<\/jats:bold>\n                    To describe clinical characteristics, attack history, and quality of life (QoL) of patients with HAE type I\/II who were receiving lanadelumab or other LTPs.\n                    <jats:bold>Methods:<\/jats:bold>\n                    Data were drawn from the Adelphi HAE Disease Specific\n Program, a cross-sectional survey of HAE physicians conducted in the United States from July to November 2021. Physician-reported disease characteristics, HAE attack frequency, and QoL were compared among patients receiving lanadelumab or other LTPs for at least 12 months.\n                    <jats:bold>Results:<\/jats:bold>\n                    Physicians reported data for 144 patients, of whom 29 had received lanadelumab and 115 had received another prophylaxis for at least 12 months. The mean \u00b1 standard deviation number of attacks in the previous 12 months was lower among patients receiving lanadelumab than other LTPs\n (2.3 \u00b1 3.1 versus 3.4 \u00b1 2.8, respectively; p\u2009=\u20090.075). Although both groups had similar current disease activity and severity, more patients receiving lanadelumab versus other LTPs had high disease activity (51.7% versus 12.5%, respectively; p\u2009&lt;\u20090.0001)\n and disease severity rated as severe (51.7% versus 16.1%, respectively; p\u2009=\u20090.0001) at diagnosis. Physicians reported that more patients who received lanadelumab had good or very good QoL (72.4%) than those receiving other LTPs (36.5%) (p\u2009=\u20090.003).\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Analysis of these findings suggests lower attack frequency, lower symptomatic impact, and better QoL in patients treated with lanadelumab than another prophylaxis in a real-world setting.\n                  <\/jats:p>","DOI":"10.2500\/aap.2024.45.240046","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T21:05:27Z","timestamp":1726693527000},"page":"426-433","source":"Crossref","is-referenced-by-count":9,"title":["Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis"],"prefix":"10.2500","volume":"45","author":[{"given":"John","family":"Anderson","sequence":"first","affiliation":[{"name":"From the Clinical Research, AllerVie Health, Birmingham, Alabama;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Soteres","sequence":"additional","affiliation":[{"name":"Allergy & Immunology, Asthma & Allergy Associates, Colorado Springs, Colorado;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffi","family":"Tachdjian","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California Los Angeles School of Medicine, Los Angeles, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Mellor","sequence":"additional","affiliation":[{"name":"Rare Diseases, Adelphi Real World, Bollington, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Earl","sequence":"additional","affiliation":[{"name":"Rare Diseases, Adelphi Real World, Bollington, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Connolly","sequence":"additional","affiliation":[{"name":"Rare Diseases, Adelphi Real World, Bollington, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Wynne-Cattanach","sequence":"additional","affiliation":[{"name":"Rare Diseases, Adelphi Real World, Bollington, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellyn","family":"Moran","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA, Inc., Lexington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystal","family":"Sing","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA, Inc., Lexington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob G.","family":"Schultz","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA, Inc., Lexington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salome","family":"Juethner","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA, Inc., Lexington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","first-page":"S292","article-title":"Severity of hereditary angioedema, prevalence, and diagnostic considerations","volume":"24","author":"Bernstein","year":"2018","journal-title":"Am J Manag Care"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014The 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"B3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2500\/aap.2023.44.230026","article-title":"Healthcare utilization of patients with hereditary angioedema treated with lanadelumab and subcutaneous C1-inhibitor concentrate","volume":"44","author":"Riedl","year":"2023","journal-title":"Allergy Asthma Proc"},{"key":"B4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.12968\/hmed.2019.80.7.391","article-title":"Hereditary angioedema: an update on causes, manifestations and treatment","volume":"80","author":"Longhurst","year":"2019","journal-title":"Br J Hosp Med (Lond)"},{"key":"B5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3949\/ccjm.80a.12073","article-title":"Recognizing and managing hereditary angioedema","volume":"80","author":"Tse","year":"2013","journal-title":"Cleve Clin J Med"},{"key":"B6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13223-019-0376-8","article-title":"The International\/Canadian Hereditary Angioedema Guideline","volume":"15","author":"Betschel","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1808012","article-title":"Hereditary angioedema","volume":"382","author":"Busse","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.anai.2020.02.018","article-title":"Patient-reported burden of hereditary angioedema: Findings from a patient survey in the United States","volume":"124","author":"Banerji","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1750-1172-9-99","article-title":"Socioeconomic burden of hereditary angioedema: Results from the hereditary angioedema burden of illness study in Europe","volume":"9","author":"Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"B11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2500\/aap.2013.34.3685","article-title":"The humanistic burden of hereditary angioedema: Results from the Burden of Illness Study in Europe","volume":"35","author":"Caballero","year":"2014","journal-title":"Allergy Asthma Proc"},{"key":"B12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.anai.2013.08.019","article-title":"The burden of illness in patients with hereditary angioedema","volume":"111","author":"Banerji","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.anai.2013.05.028","article-title":"Depression and anxiety in patients with hereditary angioedema","volume":"112","author":"Fouche","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jaip.2021.11.011","article-title":"Specific targeting of plasma kallikrein for treatment of hereditary angioedema: A revolutionary decade","volume":"10","author":"Busse","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B15","doi-asserted-by":"crossref","first-page":"23596","DOI":"10.1074\/jbc.M114.569061","article-title":"Inhibition of plasma kallikrein by a highly specific active site blocking antibody","volume":"289","author":"Kenniston","year":"2014","journal-title":"J Biol Chem"},{"key":"B16","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2018.16773","article-title":"Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial","volume":"320","author":"Banerji","year":"2018","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/all.15011","article-title":"Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study","volume":"77","author":"Banerji","year":"2022","journal-title":"Allergy"},{"key":"B18","article-title":"Highlights of prescribing information","year":"2023"},{"key":"B19","article-title":"Summary of product characteristics","year":"2023"},{"key":"B20","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: disease-specific programmes \u2014 A means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"B21","doi-asserted-by":"crossref","first-page":"e010352","DOI":"10.1136\/bmjopen-2015-010352","article-title":"Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: The Disease Specific Programme","volume":"6","author":"Babineaux","year":"2016","journal-title":"BMJ Open"},{"key":"B22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/DMSO.S120101","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: A long-term view of real-world treatment between 2000 and 2015","volume":"9","author":"Higgins","year":"2016","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B23","doi-asserted-by":"crossref","first-page":"e220188","DOI":"10.57264\/cer-2022-0188","article-title":"Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema","volume":"12","author":"Watt","year":"2023","journal-title":"J Comp Eff Res"},{"key":"B24","doi-asserted-by":"crossref","first-page":"AB131","DOI":"10.1016\/j.jaci.2022.12.413","article-title":"Effectiveness, safety, and patient-reported outcomes (PROs) in patients with hereditary angioedema (HAE) from the United States and Canada treated with lanadelumab: 24-month data from the EMPOWER study","volume":"151","author":"Wedner","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.anai.2022.08.583","article-title":"Sustained improvement in health-related quality of life with continued lanadelumab treatment in hereditary angioedema","volume":"129","author":"Watt","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B26","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.jaci.2021.05.016","article-title":"Consensus on treatment goals in hereditary angioedema: A global Delphi initiative","volume":"148","author":"Maurer","year":"2021","journal-title":"J Allergy Clin Immunol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2024\/00000045\/00000006\/art00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T23:34:28Z","timestamp":1731108868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2024.45.240046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11,1]]}},"alternative-id":["1088-5412(20241101)45:6L.426;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2024.45.240046","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}